HOME2019-03-11T17:27:49+00:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

New PD-MitoQUANT study published by CNRS researchers

May 25th, 2020|

Congratulations to Maya Bendifallah, Virginie Redeker, Elodie Monsellier, Luc Bousset*, Tracy Bellande, and Ronald Melki* for the publication of their recent study entitled: Interaction of the chaperones alpha B-crystallin and CHIP with fibrillar alpha-synuclein: Effects on internalization by cells and identification of interacting interfaces. The paper appeared in the journal [...]

COVID-19 Update

April 10th, 2020|

The current situation regarding the Coronavirus disease (COVID-19) is significantly impacting the research community, including the PD-MitoQUANT international consortium. We anticipate that the precise nature of these impacts will evolve over the coming weeks and months. Our institutions' priority is the safety and wellbeing of all people, including our own [...]

PD-MitoQUANT Partner Spotlight – H. Lundbeck A/S

April 8th, 2020|

With headquarters in Denmark, Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in research, drug discovery development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease [...]

Read more